Rheumatoid arthritis is a chronic autoimmune condition that affects the joints, causing inflammation, stiffness, and pain. Patients searching for popular rheumatoid arthritis prescriptions are often ...

The approval of the interchangeable designation was supported by data from a randomized, double-blind phase 4 trial (ClinicalTrials.gov Identifier: NCT05510063) that assessed the pharmacokinetics, ...

Humira (adalimumab) is a prescription drug used to treat hidradenitis suppurativa (HS). It helps reduce moderate to severe symptoms of this condition. Humira is also available in biosimilar forms.

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Please provide your email address to receive an email when new articles are posted on . Celltrion’s Yuflyma is a high concentration, citrate-free formulation of adalimumab. It is the ninth Humira ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...

DEAR DR. ROACH: I’m a 67-year-old healthy male, but I do take Humira for rheumatoid arthritis (RA). It does a wonderful job for me with no side effects. It does such a good job that I can periodically ...

A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...

AbbVie did not immediately respond to a request for comment, but has previously said it expects to retain a lower share of the Humira market next year. Pharmacy benefit managers, which act as ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...